Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction

被引:23
作者
Zhuang, Chunlin [1 ]
Miao, Zhenyuan [1 ]
Zhu, Lingjian [1 ]
Zhang, Yongqiang [1 ]
Guo, Zizhao [1 ]
Yao, Jianzhong [1 ]
Dong, Guoqiang [1 ]
Wang, Shengzheng [1 ]
Liu, Yang [1 ]
Chen, Hai [1 ]
Sheng, Chunquan [1 ]
Zhang, Wannian [1 ]
机构
[1] Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China
关键词
p53-MDM2; Small molecule inhibitors; Thio-benzodiazepine; Antitumor activity; IN-VIVO; P53; MDM2; ANTAGONISTS; DISCOVERY; DRUG; ACTIVATION; STRATEGY; DESIGN; CANCER;
D O I
10.1016/j.ejmech.2011.09.043
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of thio-benzodiazepine p53-MDM2 inhibitors were designed and synthesized based on the principle of bioisosterism. Most of the thio-benzodiazepines had nanomolar to micromolar affinity toward MDM2. Particularly, compounds 8a (K-i = 0.52 mu M) and 8f (K-i = 0.32 mu M) showed binding activity comparable to the positive drug nutlin-3a (K-i = 0.23 mu M). Meanwhile, compound 8j exhibited excellent antitumor activity against the U-2 OS human osteosarcoma cell line with an IC50 value of 1.06 mu M, which was about 23 times higher than that of nutlin-3a. The docking model also successfully predicted that this class of compounds mimicked three p53 critical residues binding to MDM2. The thio-benzodiazepines represent a promising class of non-peptide inhibitors of the p53-MDM2 interaction. (C) 2011 Published by Elsevier Masson SAS.
引用
收藏
页码:5654 / 5661
页数:8
相关论文
共 22 条
[2]   Inhibiting the p53-MDM2 interaction:: An important target for cancer therapy [J].
Chène, P .
NATURE REVIEWS CANCER, 2003, 3 (02) :102-109
[3]   Patented small molecule inhibitors of p53-MDM2 interaction [J].
Deng, JX ;
Dayam, R ;
Neamati, N .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (02) :165-188
[4]   Modulating the p53 pathway [J].
Dey, Anwesha ;
Lane, David P. ;
Verma, Chandra S. .
SEMINARS IN CANCER BIOLOGY, 2010, 20 (01) :3-9
[5]   Structure-based design of potent non-peptide MDM2 inhibitors [J].
Ding, K ;
Lu, Y ;
Nikolovska-Coleska, Z ;
Qiu, S ;
Ding, YS ;
Gao, W ;
Stuckey, J ;
Krajewski, K ;
Roller, PP ;
Tomita, Y ;
Parrish, DA ;
Deschamps, JR ;
Wang, SM .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2005, 127 (29) :10130-10131
[6]   A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells [J].
Galatin, PS ;
Abraham, DJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (17) :4163-4165
[7]  
Gokel G., 1971, ISONITRILE CHEM, P145, DOI DOI 10.1039/C3CC47156J
[8]   Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells [J].
Grasberger, BL ;
Lu, TB ;
Schubert, C ;
Parks, DJ ;
Carver, TE ;
Koblish, HK ;
Cummings, MD ;
LaFrance, LV ;
Milkiewicz, KL ;
Calvo, RR ;
Maguire, D ;
Lattanze, J ;
Franks, CF ;
Zhao, SY ;
Ramachandren, K ;
Bylebyl, GR ;
Zhang, M ;
Manthey, CL ;
Petrella, EC ;
Pantoliano, MW ;
Deckman, IC ;
Spurlino, JC ;
Maroney, AC ;
Tomczuk, BE ;
Molloy, CJ ;
Bone, RF .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (04) :909-912
[9]  
Hainaut P, 2000, ADV CANCER RES, V77, P81
[10]   1,4-Thienodiazepine-2,5-diones via MCR (I): Synthesis, Virtual Space and p53-Mdm2 Activity [J].
Huang, Yijun ;
Wolf, Siglinde ;
Bista, Michal ;
Meireles, Lidio ;
Camacho, Carlos ;
Holak, Tad A. ;
Doemling, Alexander .
CHEMICAL BIOLOGY & DRUG DESIGN, 2010, 76 (02) :116-129